alexa P21 Is A Master Regulator Of NF-κB-dependent Inflammation In Immune Disease And Allergic Asthma | 71387
ISSN: 2155-6121

Journal of Allergy & Therapy
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

11th International Conference on ALLERGY, ASTHMA & CLINICAL IMMUNOLOGY

Dimitrios Balomenos
National Center for Biotechnology - CSIC, Spain
ScientificTracks Abstracts: J Allergy Ther
DOI: 10.4172/2155-6121-C1-005
Abstract
Decontrolled inflammatory responses induce live-threatening disease or aggravate autoimmunity or allergy. p21 was first identified as an inhibitor and cyclin-dependent kinase 2 inhibitor (CDK2). However, other functions are now attributed to p21, as it orchestrates unique anti-inflammatory functions. p21 controls NF-κB activation, macrophage activation and LPS-induced septic shock. In the absence of p21, LPS treatment leads to increased NF-κB activation, macrophage overstimulation and excessive inflammatory production. Upon extreme TLR4 activation, macrophage hyper activation is also controlled by reprograming of hyperinflammatory microphages (M1) to a hypo responsive status (M2-like) after a secondary LPS challenge, which is known as endotoxin tolerance. We recently reported that p21 promotes M1-to-M2 polarization, as p21-/- macrophages showed impaired ability to reprogram. p21 shifts the balance between active p65/p50 and inhibitory p50/p50 NF-κB and promotes macrophage reprogramming by favoring DNAbinding affinity of p50/p50 homodimers, which limit IFN-Υ production. The first association of p21 with the immune response was its identification as an autoimmunity suppressor, and it was assumed to control T cell proliferation. However, our latest findings show that lack of p21 drives lupus-like disease by augmenting the activation status of T cells. The major characteristic of this hype activation is the elevated production of IFN-gamma by T cells, a major inducer of lupus autoimmunity. Our findings point to p21 as an early regulator of T cell activation that controls mitochondrial ROS production. Finally, in agreement with effect of p21 on the excessive immune responses, p21-deficient mice developed extreme allergic asthma when subjected to the allergy-inducing OVA model, exhibiting severe pneumonitis and striking perivascular and interstitial inflammation compare to controls. Overall p21 emerges as a global guardian of hyperresponsivess in inflammatory, autoimmune and allergic pathologies at both the macrophage and T cell levels.
Biography

Dimitrios Balomenos received his PhD of Rutgers University, NJ. and continued his postdoctoral training at the Scripps Research Institute (La Jolla, Ca) and in the Department of Immunology and Oncology of CNB/CSIC in Madrid, Spain. In 2002 he was awarded an independent group research contract and from 2010 he is a tenured group leader at CNB/CSIC. Major discoveries include the absolute requirement of IFN-gamma for Systemic Lupus Erythematosus pathogenesis, (D. Balomenos et al, J. Clin. Invest. 1997), the discovery of p21-dependent pathways for regulation of T cell tolerance and autoimmunity (D. Balomenos et al, Nat. Med. 2000), and the requirement for p21 in reprogramming of M1-to-M2 macrophages, though the regulation of p50/p50 NF-kB and IFN-beta expression (Rackov et al, 2016). The group focuses in understanding how p21 and other molecules restrain extreme immune responses and discover p21 molecular patners that control ecssessive infalmmation and might harbor potential treatment capacity.

image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7